Adipose-derived stem cells
PreclinicalCell therapy
Adipose-derived stem cells is one of 21 biologic programs targeting Macular Degeneration. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Macular Degeneration
#DrugCompanyPhaseTrials
1Vabysmo
RocheApproved
Copaxone
TevaApproved
Iheezo
BB. Braun Medical Inc.
Approved
Avastin
RochePhase 3
Visudyne
BBausch Health Americas, Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
OTX-TKI
OOcular Therapeutix, Inc.
Phase 3
Tiespectus
EEyeBiotech Ltd.
Phase 3
Faricimab Injection [vabysmo]
CCincinnati Eye Institute, Southwest Ohio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease1 trial
Ultrasound1 trial
Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD
Completed·—·Phase 1·NCT02756884·10 enrolled
Macular Degeneration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adipose-derived stem cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- XXuzhou Medical University